CYP2E1 and hepatocellular carcinoma: Of these pathways, our previous data demonstrated that CYP2E1 metabolic activity was significantly increased in livers from HCC patients [21], and inhibition of CYP2E1 activity significantly decreased liver injury and liver carcinogenesis in rats induced by diethylnitrosamine (DEN) [25].